Chirag M Vyas1, Macarius Donneyong2, David Mischoulon1, Grace Chang3, Heike Gibson4, Nancy R Cook4,5, JoAnn E Manson4,5,6, Charles F Reynolds7, Olivia I Okereke1,5,6. 1. Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston. 2. College of Pharmacy, The Ohio State University, Columbus. 3. Department of Psychiatry, VA Boston Healthcare System, Brockton, Massachusetts. 4. Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 5. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. 6. Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 7. Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Abstract
Importance: Knowledge gaps persist regarding racial and ethnic variation in late-life depression, including differences in specific depressive symptoms and disparities in care. Objective: To examine racial/ethnic differences in depression severity, symptom burden, and care. Design, Setting, and Participants: This cross-sectional study included 25 503 of 25 871 community-dwelling older adults who participated in the Vitamin D and Omega-3 Trial (VITAL), a randomized trial of cancer and cardiovascular disease prevention conducted from November 2011 to December 2017. Data analysis was conducted from June to September 2018. Exposure: Racial/ethnic group (ie, non-Hispanic white; black; Hispanic; Asian; and other, multiple, or unspecified race). Main Outcomes and Measures: Depressive symptoms, assessed using the Patient Health Questionnaire-8 (PHQ-8); participant-reported diagnosis, medication, and/or counseling for depression. Differences across racial/ethnic groups were evaluated using multivariable zero-inflated negative binomial regression to compare PHQ-8 scores and multivariable logistic regression to estimate odds of item-level symptom burden and odds of depression treatment among those with diagnosed depression. Results: There were 25 503 VITAL participants with adequate depression data (mean [SD] age, 67.1 [7.1] years) including 12 888 [50.5%] women, 17 828 [69.9%] non-Hispanic white participants, 5004 [19.6%] black participants, 1001 [3.9%] Hispanic participants, 377 [1.5%] Asian participants, and 1293 participants [5.1%] who were categorized in the other, multiple, or unspecified race group. After adjustment for sociodemographic, lifestyle, and health confounders, black participants had a 10% higher severity level of PHQ-8 scores compared with non-Hispanic white participants (rate ratio [RR], 1.10; 95% CI, 1.04-1.17; P < .001); Hispanic participants had a 23% higher severity level of PHQ-8 scores compared with non-Hispanic white participants (RR, 1.23; 95% CI, 1.10-1.38; P < .001); and participants in the other, multiple, or unspecified group had a 14% higher severity level of PHQ-8 scores compared with non-Hispanic white participants (RR, 1.14; 95% CI, 1.04-1.25; P = .007). Compared with non-Hispanic white participants, participants belonging to minority groups had 1.5-fold to 2-fold significantly higher fully adjusted odds of anhedonia (among black participants: odds ratio [OR], 1.76; 95% CI, 1.47-2.11; among Hispanic participants: OR, 1.96; 95% CI, 1.43-2.69), sadness (among black participants: OR, 1.31; 95% CI, 1.07-1.60; among Hispanic participants: OR, 2.09; 95% CI, 1.51-2.88), and psychomotor symptoms (among black participants: OR, 1.77; 95% CI, 1.31-2.39; among Hispanic participants: OR, 2.12; 95% CI, 1.28-3.50); multivariable-adjusted odds of sleep problems and guilt appeared higher among Hispanic vs non-Hispanic white participants (sleep: OR, 1.24; 95% CI, 1.01-1.52; guilt: 1.84; 95% CI, 1.31-2.59). Among those with clinically significant depressive symptoms (ie, PHQ-8 score ≥10) and/or those with diagnosed depression, black participants were 61% less likely to report any treatment (ie, medications and/or counseling) than non-Hispanic white participants after adjusting for confounders (adjusted OR, 0.39; 95% CI, 0.27-0.56). Conclusions and Relevance: In this cross-sectional study, significant racial and ethnic differences in late-life depression severity, item-level symptom burden, and depression care were observed after adjustment for numerous confounders. These findings suggest a need for further examination of novel patient-level and clinician-level factors underlying these associations.
Importance: Knowledge gaps persist regarding racial and ethnic variation in late-life depression, including differences in specific depressive symptoms and disparities in care. Objective: To examine racial/ethnic differences in depression severity, symptom burden, and care. Design, Setting, and Participants: This cross-sectional study included 25 503 of 25 871 community-dwelling older adults who participated in the Vitamin D and Omega-3 Trial (VITAL), a randomized trial of cancer and cardiovascular disease prevention conducted from November 2011 to December 2017. Data analysis was conducted from June to September 2018. Exposure: Racial/ethnic group (ie, non-Hispanic white; black; Hispanic; Asian; and other, multiple, or unspecified race). Main Outcomes and Measures: Depressive symptoms, assessed using the Patient Health Questionnaire-8 (PHQ-8); participant-reported diagnosis, medication, and/or counseling for depression. Differences across racial/ethnic groups were evaluated using multivariable zero-inflated negative binomial regression to compare PHQ-8 scores and multivariable logistic regression to estimate odds of item-level symptom burden and odds of depression treatment among those with diagnosed depression. Results: There were 25 503 VITAL participants with adequate depression data (mean [SD] age, 67.1 [7.1] years) including 12 888 [50.5%] women, 17 828 [69.9%] non-Hispanic white participants, 5004 [19.6%] black participants, 1001 [3.9%] Hispanic participants, 377 [1.5%] Asian participants, and 1293 participants [5.1%] who were categorized in the other, multiple, or unspecified race group. After adjustment for sociodemographic, lifestyle, and health confounders, black participants had a 10% higher severity level of PHQ-8 scores compared with non-Hispanic white participants (rate ratio [RR], 1.10; 95% CI, 1.04-1.17; P < .001); Hispanic participants had a 23% higher severity level of PHQ-8 scores compared with non-Hispanic white participants (RR, 1.23; 95% CI, 1.10-1.38; P < .001); and participants in the other, multiple, or unspecified group had a 14% higher severity level of PHQ-8 scores compared with non-Hispanic white participants (RR, 1.14; 95% CI, 1.04-1.25; P = .007). Compared with non-Hispanic white participants, participants belonging to minority groups had 1.5-fold to 2-fold significantly higher fully adjusted odds of anhedonia (among black participants: odds ratio [OR], 1.76; 95% CI, 1.47-2.11; among Hispanic participants: OR, 1.96; 95% CI, 1.43-2.69), sadness (among black participants: OR, 1.31; 95% CI, 1.07-1.60; among Hispanic participants: OR, 2.09; 95% CI, 1.51-2.88), and psychomotor symptoms (among black participants: OR, 1.77; 95% CI, 1.31-2.39; among Hispanic participants: OR, 2.12; 95% CI, 1.28-3.50); multivariable-adjusted odds of sleep problems and guilt appeared higher among Hispanic vs non-Hispanic white participants (sleep: OR, 1.24; 95% CI, 1.01-1.52; guilt: 1.84; 95% CI, 1.31-2.59). Among those with clinically significant depressive symptoms (ie, PHQ-8 score ≥10) and/or those with diagnosed depression, black participants were 61% less likely to report any treatment (ie, medications and/or counseling) than non-Hispanic white participants after adjusting for confounders (adjusted OR, 0.39; 95% CI, 0.27-0.56). Conclusions and Relevance: In this cross-sectional study, significant racial and ethnic differences in late-life depression severity, item-level symptom burden, and depression care were observed after adjustment for numerous confounders. These findings suggest a need for further examination of novel patient-level and clinician-level factors underlying these associations.
Authors: Olivia I Okereke; Charles F Reynolds; David Mischoulon; Grace Chang; Nancy R Cook; Trisha Copeland; Georgina Friedenberg; Julie E Buring; JoAnn E Manson Journal: Contemp Clin Trials Date: 2018-03-08 Impact factor: 2.226
Authors: JoAnn E Manson; Nancy R Cook; I-Min Lee; William Christen; Shari S Bassuk; Samia Mora; Heike Gibson; Christine M Albert; David Gordon; Trisha Copeland; Denise D'Agostino; Georgina Friedenberg; Claire Ridge; Vadim Bubes; Edward L Giovannucci; Walter C Willett; Julie E Buring Journal: N Engl J Med Date: 2018-11-10 Impact factor: 91.245
Authors: Judith H Lichtman; J Thomas Bigger; James A Blumenthal; Nancy Frasure-Smith; Peter G Kaufmann; François Lespérance; Daniel B Mark; David S Sheps; C Barr Taylor; Erika Sivarajan Froelicher Journal: Circulation Date: 2008-09-29 Impact factor: 29.690
Authors: Hendrika J Luijendijk; Julia F van den Berg; Marieke J H J Dekker; Hendrik R van Tuijl; Wim Otte; Filip Smit; Albert Hofman; Bruno H C Stricker; Henning Tiemeier Journal: Arch Gen Psychiatry Date: 2008-12
Authors: Aartjan T F Beekman; Sandra W Geerlings; Dorly J H Deeg; Jan H Smit; Robert S Schoevers; Edwin de Beurs; Arjan W Braam; Brenda W J H Penninx; Willem van Tilburg Journal: Arch Gen Psychiatry Date: 2002-07
Authors: Chirag M Vyas; Charles F Reynolds; Macarius Donneyong; David Mischoulon; Grace Chang; Nancy R Cook; JoAnn E Manson; Olivia I Okereke Journal: Am J Geriatr Psychiatry Date: 2021-11-27 Impact factor: 4.105
Authors: Chirag M Vyas; Soshiro Ogata; Charles F Reynolds; David Mischoulon; Grace Chang; Nancy R Cook; JoAnn E Manson; Marta Crous-Bou; Immaculata De Vivo; Olivia I Okereke Journal: Age Ageing Date: 2021-05-05 Impact factor: 10.668
Authors: Samantha E John; Sarah A Evans; Bona Kim; Petek Ozgul; David W Loring; Monica Parker; James J Lah; Allan I Levey; Felicia C Goldstein Journal: Neuropsychol Dev Cogn B Aging Neuropsychol Cogn Date: 2021-08-12
Authors: Mario Cruz-Gonzalez; Patrick E Shrout; Kiara Alvarez; Isaure Hostetter; Margarita Alegría Journal: Front Psychiatry Date: 2021-02-15 Impact factor: 4.157
Authors: Kimberly A Van Orden; Julie Lutz; Kenneth R Conner; Caroline Silva; Michael J Hasselberg; Kathleen Fear; Allison W Leadley; Marsha N Wittink; Judith F Baumhauer Journal: Front Psychiatry Date: 2022-01-11 Impact factor: 5.435